Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12961363 | 0.83 | ALDH1A1 (0.57) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| SCHEMBL17225122 | 0.82 | ALDH1A1 (0.56) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| SCHEMBL18388507 | 0.82 | NPSR1 (0.56) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| SCHEMBL11925250 | 0.74 | LIPE (0.46) | ALDH1A1LMNACYP3A4TSHRNFKB1 | |
| SCHEMBL31434238 | 0.73 | ALDH1A1 (0.46) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| Chlorpropamide SCHEMBL1537108 | 0.71 | ALDH1A1 (1.00) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| Chlorpropamide SCHEMBL23947 | 0.71 | ALDH1A1 (1.00) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| SCHEMBL11448337 | 0.70 | HSD11B1 (0.51) | SMN1; SMN2PSEN1PSEN2APH1BNCSTN | |
| Chlorpropamide SCHEMBL28353575 | 0.70 | ALDH1A1 (0.97) | ALDH1A1NPSR1LMNACYP3A4THRB | |
| SCHEMBL8602183 | 0.69 | CA12 (0.59) | NPSR1LMNASMN1; SMN2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2012088441-A1 | MULTI- API LOADING PRODRUGS | ALKERMES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | ALDH1A1 525/4885NPSR1 1143/4885LMNA 2855/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | ALDH1A1 525/4885NPSR1 1143/4885LMNA 2855/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | ALDH1A1 525/4885NPSR1 1143/4885LMNA 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.